MedTrace Logo

WATER III: Aquablation vs. Transurethral Laser Enucleation of Large Prostates (80 - 180mL) in Benign Prostatic Hyperplasia

NCT04801381 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 202

Last updated 2025-02-06

No results posted yet for this study

Summary

Comparative analysis of efficacy and safety of Aquablation (AQUABEAM Robotic System®, PROCEPT BioRobotics, Redwood City, CA, USA) and transurethral laser enucleation as surgical therapy for benign prostatic hyperplasia with large prostates (80-180ml).

Conditions

  • BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms

Interventions

PROCEDURE

Aquablation therapy

Aquablation is carried out with the AQUABEAM Robotic System®, PROCEPT BioRobotics, Redwood City, CA, USA

PROCEDURE

Transurethral laser enucleation

Transurethral laser enucleation is performed according to the standard established at the respective test center. Included laser techniques: Holmium laser (HoLEP) and Thulium laser (ThuLEP).

Sponsors & Collaborators

  • PROCEPT BioRobotics

    collaborator INDUSTRY

  • University of Bonn

    lead OTHER

Principal Investigators

  • Manuel Ritter, Univ.-Prof. Dr. med. · Department of Urology, University of Bonn

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-16
Primary Completion
2025-01-16
Completion
2029-10-31

Countries

  • Germany
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04801381 on ClinicalTrials.gov